ARS PHARMACEUTICALS INC. - COMMON STOCK

ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

20 يونيو 2023 08:00:01 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results

15 مايو 2023 09:00:00 بحسب Nasdaq GlobeNewswire

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

11 مايو 2023 19:01:24 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis

09 مايو 2023 09:10:46 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

28 مارس 2023 09:39:51 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

23 مارس 2023 16:01:00 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

23 فبراير 2023 16:01:00 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis

22 فبراير 2023 16:05:01 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

09 فبراير 2023 06:30:00 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

10 نوفمبر 2022 08:00:03 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

08 نوفمبر 2022 16:02:00 بحسب Nasdaq GlobeNewswire